Metric Finance
LearnFAQ
LearnFAQ

Learn / PTCT

NASDAQ: PTCT

Ptc Therapeutics (PTCT) stock, explained like you're 5

Ptc Therapeutics trades on the Nasdaq under the ticker PTCT. It is a mid cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 5.4 billion dollars.

Ticker
PTCT
Exchange
Nasdaq
Sector
Healthcare
Industry
Pharmaceutical Preparations
Size
Mid cap, about 5.4 billion dollars

Is Ptc Therapeutics a small, medium or large cap company?

No. Ptc Therapeutics is a mid cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 5.4 billion dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Ptc Therapeutics makes money

  • Selling medicines, medical devices or healthcare services.
  • Insurance premiums or hospital and clinic fees.
  • Research and licensing deals.

What moves PTCT stock

  • Results from clinical trials and approvals from regulators.
  • Drug prices, insurance rules and government policy.
  • Patents running out and new competing treatments.

In the news lately

  • PTC Therapeutics, Inc. (PTCT) Stock Price, News, Quote & History (Yahoo! Finance Canada)
  • PTC Therapeutics (NASDAQ:PTCT) Stock Rating Raised to "Strong Buy" at UBS Group (MarketBeat)
  • A rare disease drugmaker's Oct. 29 webcast includes a business update; replay stays online for 30 days. (Stock Titan)
  • PTC Therapeutics (PTCT) Stock Looks About Right At This Price (Simply Wall Street)
  • Ptc Therapeutics stock hits 52 week low at $61.20 (Investing.com)

Follow PTCT in your daily brief

Each trading day at 5 PM ET we post what happened to Ptc Therapeutics and why it matters, in simple words. Free.

Start my free brief

Key terms to know before you follow PTCT

  • Market cap
  • P/E ratio
  • EPS (earnings per share)
  • Earnings report
  • Volatility

Questions about Ptc Therapeutics stock

What does Ptc Therapeutics do?

Ptc Therapeutics trades on the Nasdaq under the ticker PTCT. It is a mid cap company in the pharmaceutical preparations industry, part of the healthcare sector, with a market value of about 5.4 billion dollars.

What is the ticker symbol for Ptc Therapeutics?

Ptc Therapeutics trades under the ticker PTCT on the Nasdaq.

What is Ptc Therapeutics's market cap?

Ptc Therapeutics is a mid cap stock with a market cap of about 5.4 billion dollars.

How does Ptc Therapeutics make money?

Selling medicines, medical devices or healthcare services. Insurance premiums or hospital and clinic fees. Research and licensing deals.

What moves PTCT stock?

Results from clinical trials and approvals from regulators. Drug prices, insurance rules and government policy. Patents running out and new competing treatments.

How can I follow PTCT stock every day?

Add PTCT to your watchlist on Metric Finance. We post a free brief every trading day at 5 PM ET that explains what happened to the stocks you follow, in simple words.

Follow PTCT daily

A free brief on Ptc Therapeutics and your other stocks, every trading day at 5 PM ET.

Start my free brief

Similar stocks

  • NVS · Novartis AG
  • AZN · Astrazeneca PLC
  • NVO · Novo Nordisk A S
  • VRTX · Vertex Pharmaceuticals Inc / Ma

Similar stocks

  • NVSNovartis AG
  • AZNAstrazeneca PLC
  • NVONovo Nordisk A S
  • VRTXVertex Pharmaceuticals Inc / Ma

Compare PTCT: PTCT vs NVS, PTCT vs AZN, PTCT vs NVO

Educational information, not financial advice. This guide explains the business in general terms and does not include live prices.

Metric Finance

Stocks explained like you're 5.

Product

  • Learn
  • FAQ
  • Your account

Legal

  • Privacy
  • Terms

Support

  • Contact
  • Unsubscribe

© 2026 Metric Finance

Built by Yashna & Vansh · Not investment advice · Market data may be delayed